Could Umbilical Cord Blood & CRISPR Unlock New Gene Therapy Treatment for Celiac Disease?
When our son Jax was diagnosed with Celiac Disease in August 2018, he was five years old and preparing to start Kindergarten. He had severe iron deficiency anemia and significant damage to his small intestine. Our family suddenly faced a lifelong autoimmune disease that would change how we approached every bite, every day.
We also faced questions that a diagnosis could not answer. Why had Jax developed Celiac? When had the disease activated? Why had other members of our family who carry the genetic risk factors not developed Celiac Disease?
Those questions led us to consider something we had preserved years earlier: Jax’s umbilical cord blood.
Could cells collected at his birth and cryogenically preserved help researchers understand what happened between genetic susceptibility and the development of Celiac? Could comparing those cells with present-day biological samples reveal molecular changes -- and help identify potential targets for research using CRISPR technologies?
CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. The name describes repeating DNA sequences first discovered in microbes. Scientists adapted this natural microbial defense system into tools that can precisely target DNA to edit genes or change their activity.
Our idea begins with using preserved umbilical cord blood as a biological reference point from birth. Researchers could compare those samples with samples collected after Celiac developed to investigate differences in gene activity, immune regulation, and other molecular features. The challenge would be to distinguish changes associated with normal development from those that precede, contribute to, or result from the disease.
CRISPR could help researchers test which of those differences matter -- and whether modifying the underlying mechanisms could inform a treatment or, ultimately, a cure through gene therapy or another novel approach.
Beyond testing findings from cord blood comparisons, CRISPR also offers ways to investigate broader treatment possibilities. Could researchers engineer immune cells that promote tolerance to Gluten, modify how Gluten is presented to the immune system, or interrupt the inflammatory signals that damage the intestine?
These connected avenues of research frame the possibility we want to explore: whether a biological record preserved at birth, combined with tools for studying and modifying gene function, could help unlock new treatments for Celiac Disease.
An April 2026 NIH-funded breakthrough involving an enhanced CRISPR gene-editing system adds another dimension: the possibility of expanding how gene-editing tools could eventually reach disease-relevant cells inside the body.
Together, these possibilities support exploring a phased research program that begins with discovery, tests potential mechanisms, and evaluates whether the findings could inform new treatments.
A Biological Reference Point from Birth: Life Before Celiac
There is so much that is unknown about Celiac Disease, and there is so much that is misunderstood. One potential way of unraveling its mysteries would be to better understand antecedent Celiac Disease. In other words, life before Celiac.
Our family banked the cord blood of both of our children at birth, and those cells remain cryogenically preserved. For Jax, that collection provides a biological reference point from before dietary Gluten exposure, his documented iron deficiency, and his Celiac diagnosis.
We think of his cord blood as a molecular time machine: preserved cells from years before his autoimmune disease was diagnosed and likely before it developed.
Our premise is to compare these birth samples with present-day samples and investigate what may be different. Think of it as comparing versions of a document in Microsoft Word: an original and a later version, with changes highlighted in red. Similarly, researchers can similarly use color-coded maps to highlight molecular differences between biological samples -- for example, red for genes that are more active and blue for genes that are less active. Comparing umbilical cord blood preserved at birth with present-day samples could help reveal what has changed over time. The next challenge would be determining which differences reflect normal development, which are consequences of Celiac, and which may help explain how the disease developed.
Biology is more complicated. Developing Celiac does not ordinarily mean that someone's inherited DNA sequence has changed. Genetic susceptibility was already present at birth. One idea is for researchers could instead investigate differences in gene activity, epigenetic regulation -- the mechanisms that help control how genes are used -- and the composition and behavior of immune cells.
The underlying question remains: what has changed, which changes matter, and is there something that can be modified to reduce or reverse the disease process?
Comparing siblings’ birth and present-day samples could also help researchers investigate why Celiac develops in one child and not another in the same family. Existing prenatal genetic test results might provide additional context, depending on what those tests measured.
A birth sample should not automatically be considered a completely unaffected biological baseline. Factors relevant to later disease may already be present. That possibility makes the sample valuable in a different way: it may help researchers distinguish early susceptibility from changes associated with later disease.
Why Celiac Offers an Intriguing Research Opportunity
Celiac is an autoimmune disease driven by an inappropriate immune response to Gluten in genetically susceptible individuals, most commonly those carrying particular HLA variants encoding HLA-DQ2 or HLA-DQ8 molecules. These molecules bind and display Gluten peptides, particularly peptides modified by the enzyme transglutaminase 2, to CD4+ T cells. This contributes to chronic intestinal inflammation, villous damage, and widespread symptoms.
Despite advances in diagnosis and management, a strict lifelong Gluten Free diet remains the only available treatment. A Gluten Free diet is highly burdensome, costly, challenging to maintain, and insufficient for some patients who continue to experience symptoms or mucosal damage. There is also no rescue medicine available (i.e., EpiPen) in the event of accidential ingestion of Gluten. A therapy capable of addressing the immunologic basis of Gluten reactivity could represent a transformative advance.
Our family’s experience illustrates the questions that remain. All four of us carry Celiac-associated HLA genes, yet Celiac only activated in Jax. That pattern does not explain what caused his disease, but it motivates our interest in understanding why inherited susceptibility produces different outcomes.
Research following children from early life already offers an important foundation. The Celiac Disease Genomic, Environmental, Microbiome and Metabolomic study, known as CDGEMM, included cord-blood collection for a biorepository and epigenetic studies in its 2015 study design. Its 2023 cohort update described further genomic, immune-cell, and epigenetic analyses among the next steps.
Other investigators have examined cord blood and newborn blood samples in children who later developed Celiac. A 2020 study found no overall association between maternal cells detected in cord blood and subsequent Celiac risk, while a 2025 study found no association between selected newborn immune-cell markers and later disease. These findings address specific hypotheses; they leave open whether broader comparisons of preserved birth samples with later biological samples could reveal mechanisms relevant to Celiac development and potential treatment targets.
Our proposed research would build on this foundation by investigating what additional insight paired banked birth samples and later samples could provide.
Building a Research Cohort
An exploratory cohort of approximately 50–100 children with confirmed Celiac Disease who have their umbilical cord blood banked could provide valuable data. Siblings without diagnosed Celiac who also have banked cord blood could be recruited as an additional comparison group where available. The appropriate enrollment would depend on the study’s objectives, sample availability and quality, and a formal statistical assessment.
Through Celiac Journey’s community building and engagement, we have met families whose children receive care at Penn Medicine and Children's Hospital of Philadelphia and have cord blood stored with various banks. These relationships offer a potential starting point for assessing recruitment feasibility.
Before committing valuable stored material, researchers would need to determine which analyses the samples can support, how much material is available, and how storage and processing might affect results.
The comparisons would require careful controls. Newborn and adolescent immune systems differ naturally, and cord blood and later peripheral blood contain different mixtures of cell types. Blood samples also cannot fully represent what happens in the intestine. Diet, treatment, infections, and current disease activity could influence the findings.
These are testable hypotheses. The initial goal would be to identify reproducible differences and candidate mechanisms for further investigation. Establishing their relevance to Celiac would require replication and functional testing.
Using CRISPR to Test What the Comparisons Reveal
CRISPR technologies could help connect the discovery of molecular differences with an understanding of their function.
If sample comparisons identify a candidate gene or regulatory pathway, researchers could use CRISPR tools in lab models to investigate whether changing its activity alters the response to Gluten. This would help distinguish a biological marker associated with Celiac from a mechanism that contributes to it.
CRISPR interference and CRISPR activation, known as CRISPRi and CRISPRa, can reduce or increase the activity of selected genes without cutting the DNA sequence. Their effects and duration depend on the particular system and how it is delivered.
These tools offer potential approaches for preclinical studies focused on modifying antigen presentation, inflammatory signaling, or immune regulation. The findings could guide several kinds of treatment development: a useful target might ultimately be addressed through a medication or engineered cell therapy.
Engineering Immune Cells to Promote Gluten Tolerance
One promising strategy is to enhance immune regulatory pathways to promote tolerance to Gluten. Possible research directions include supporting FOXP3-dependent regulatory T-cell function or encouraging dendritic cells to promote tolerance rather than inflammation. These approaches would require testing to determine which modifications produce stable, appropriately targeted effects.
There is already encouraging preclinical evidence for engineering Gluten-specific regulatory T cells. In a study published in Science Translational Medicine in March 2025, researchers engineered these cells and evaluated their activity in laboratory experiments and an HLA-DQ2.5 transgenic mouse model. The engineered cells suppressed the proliferation and intestinal migration of Gluten-reactive effector T cells.
These findings support further investigation; they do not establish a safe or effective treatment for people with Celiac. Our proposed contribution is to investigate whether information preserved at birth could help identify additional mechanisms or guide the selection of targets for such research.
Investigating How Gluten Activates an Aberrant Immune System Response
Another research direction would examine whether CRISPR could selectively reduce or modify the activity of disease-associated HLA-DQ2/DQ8 molecules, diminishing their ability to present Gluten peptides and drive pathogenic T-cell activation.
Celiac offers a defined interaction to study because its dietary trigger, major genetic risk factors, and important steps in its immune response are well characterized. Researchers could test whether targeted changes in HLA expression or function reduce Gluten-related T-cell activation in experimental models.
The challenge is substantial. Antigen presentation also supports protective immunity. Any proposed intervention would need to preserve essential immune functions while reducing the Celiac Disease-associated autoimmune response. Selective approaches would therefore require extensive laboratory investigation before their therapeutic potential could be assessed.
Investigating the Signals that Damage the Intestine
The immune response in Celiac extends beyond the initial recognition of Gluten. Inflammatory signals help activate cells that damage the intestinal lining.
Research published in Nature in 2020 implicated interleukin-15, or IL-15, in Gluten-dependent intestinal destruction in a mouse model. A separate human organoid study published in Nature in 2024 identified interleukin-7, or IL-7, as a contributor to epithelial destruction in that experimental system.
CRISPR-based experiments could test whether changing selected genes within these pathways reduces Gluten-induced injury. Such studies would need to examine effects on normal immune function as well as disease-related activity.
Another candidate is TGM2, the gene encoding transglutaminase 2, or TG2. This enzyme modifies Gluten peptides in ways that enhance their ability to stimulate disease-associated T cells. A randomized clinical trial published in 2021 found that a TG2-inhibiting drug reduced Gluten-induced intestinal damage during a controlled Gluten challenge.
That finding supports the pathway’s relevance, but it does not establish that genetic alteration of TGM2 would be safe or effective. CRISPR could help clarify where and when these mechanisms matter, potentially informing treatments that do not require permanent genetic changes.
Testing Ideas in Patient-Derived Intestinal Models
Patient-derived intestinal organoids could provide a complementary platform for this research.
Scientists have developed Celiac organoids that preserve intestinal tissue alongside resident immune cells and reproduce aspects of Gluten-induced injury. These systems offer a way to study interactions that cannot be fully captured by blood samples alone.
Combining suitable organoid models with CRISPR experiments could help researchers assess whether candidate mechanisms identified through sample comparisons influence intestinal damage. This would provide an additional step between discovering a molecular difference and considering a clinical intervention.
Smaller CRISPR Tools Could Expand Future Gene Therapy Delivery Options
An NIH-funded breakthrough announced on April 13, 2026, illustrates how CRISPR technology continues to evolve. Researchers at the University of Texas at Austin identified a compact gene-editing enzyme called Al3Cas12f and engineered an enhanced version, Al3Cas12f RKK, with improved editing activity in human cells.
The underlying study, published in Nature Structural & Molecular Biology, describes an editor whose small size makes it a candidate for packaging into adeno-associated virus, or AAV, vectors used to deliver genetic instructions into cells.
Size matters because delivery systems have limited carrying capacity. A smaller gene editor could make it easier to package the components needed for gene editing, potentially expanding options for interventions performed directly inside the body.
For Celiac research, this raises a future question: could compact editors eventually help researchers modify selected intestinal or immune-cell populations involved in harmful responses to Gluten?
The research did not test a Celiac treatment or demonstrate successful delivery to the relevant cells in a living person. NIH reported that testing the editor packaged into AAV vectors was a planned next step. Smaller size also does not, by itself, solve the challenges of reaching the correct cells, avoiding unintended edits, and preserving normal immune function.
Nevertheless, the advance is relevant to the longer-term possibilities explored here. Our proposed cord-blood comparisons would seek to identify mechanisms worth targeting; improvements in CRISPR engineering and delivery could expand the tools available to investigate those targets and potentially develop future therapies.
Moving Toward Treatment in Stages
Developing CRISPR-based strategies for Celiac is scientifically plausible, but translating them into a clinical therapy is complex and requires phased, risk-aware research.
Our proposal begins with learning from preserved umbilica cord blood samples. It does not assume that reinfusing newborn cells could reset a child’s immune system or reverse Celiac, albeit that presents some thought provoking ideas on reinfusing a portion of newborn cells.
Early work would focus on identifying reproducible differences, testing their biological significance, and evaluating candidate interventions in laboratory models. Ex vivo editing -- modifying cells outside the body -- could provide a controlled platform for studying a patient’s own immune cells before considering any clinical application. It would allow substantial assessment of editing specificity, cell function, and unintended effects, although ex vivo editing can still produce permanent genomic changes.
Laboratory results alone cannot establish how an intervention will behave in a patient. Further safety studies, regulatory review, and clinical trials would be necessary.
The long-term ambition is to move from avoiding Gluten and navigating the adverse effects of accidental ingestion toward treatments that address the mechanisms driving disease. Durable immune tolerance could potentially reduce disease activity, lessen dietary restrictions, and improve long-term health outcomes. Earlier successes could include identifying a new treatment target or reducing intestinal injury from accidental exposure.
Success in Celiac research might also inform precision approaches to other autoimmune diseases, although each disease would require its own investigation.
A Research Invitation Grounded in Lived Experience
As parents and patient advocates, we bring questions shaped by navigating daily life with Celiac Disease. Answering them requires collaboration with scientists experienced in pediatric gastroenterology, immunology, cord blood biology, epigenetics, and gene editing.
Our proposal asks whether biological information collected at birth could help explain the development of disease -- and whether CRISPR technologies could help researchers turn that knowledge into new treatment strategies.
For our family, the ambition is deeply personal. We want Jax and others living with Celiac to have treatment options that reduce the constant burden of avoiding Gluten.
We want to prevent the activation of Celiac Disease in the 40% of the general population who are genetically at-risk to develop Celiac at any point in their life.
Cells preserved at birth may offer one resource for pursuing that goal. Studying them alongside advances in immune-cell engineering, disease modeling, and CRISPR delivery could help researchers determine which paths deserve further investigation and investment.
